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cultures.3
microenvironment  and  detennining  the types  and  concentration  of molecules  present  such  as
growth factors and cytokines 1,12.1'.
Cartilage  degeneration  in OA is the result  of events  including enzymatic  degradation  of
matrix  components  and  malfunction  of the intracellular  signaling  pathways  in chondrocytes  2,
The breakdown  of collagen  fibrils causes  matrix instability while the  degradation  of aggrecan
results  in the loss  offixed charges  important  in maintaining  the cushioning  function of cartilage2
Normally, mechanical  stress  and  enzymatic  activities  in joints cause  molecular  damage  that is
compensated  by the natural  turnover  of matrix components  t. However  if catabolic  lK;tivities
begin to outpace anabolic activities, the matrix degenerates  and the cartilage becomes  damaged 1
The initial stages  of cartilage  damage  begin in the superficial  and  upper  middle  zones  and  then
progress  to deeper  cartilage  layers  as  OA develops  in the  joint.  In severe  disease,  cartilage  may
be  absent  in some  areas  of the  joint and  lesions  may  extend  to the  bone'. In addition  to matrix
perturbations,  the integrity of chondrocytes  is also  compromised  in OA.  In vitro studies  of
articular  cartilage  degradation  induced  by the catabolic  cytokine,  interleukin (IL-l),  indicate
signal  transduction  pathways  mooiated  by the Rho subfamily  of small G-proteins,  or GTPases
that includes Cdc42, Rac, and RhoA, are altered  16, Thus the Rho GTPases  may also be affected
in naturally O(;Currlng  OA.  These GTPases  are important to cartilage biology  since they control
the  organization  of die actin cytoskeleton  and  morphology  is tightly linked to control  of cell
phenotype  17.  Cartilage  is an  avascular  and  anerval  tissue,  which limits its regenerative
capabilities  '. Thus,  understanding  the regulation  of the extracellular  matrix and  actin
cytoskeleton  of chondrocytes  is vital to elucidating  the mechanisms  involved in the development
ofOA,
Interleukin-1
The pro-inf1arnmatory  cytokine  IL-I,  also  referred  to as  catabolin,  has  been  used  since
1980  to study  the molecular  mechanisms  that cause  cartilage  degradation  in OA 1,4.  IL-l  is4
predominately  produced  by monocytes  IS in two isofonns  OL-l a and  1L-1  P),  both of which have
contributed  to the con-ent  understanding  of cartilage  degradation  4. An increase  in the
concentration  of IL-l  in synovial  fluids, which bathe  the  joint, has  been  observed  in rheumatoid
arthritis (an  autoimmune  disease),  and  to a lesser  extent  in OA 1.  IL-l  has  been  shown  to induce
the OA phenotype  in vitro by causing  a down-regulation  in the expression  of the anabolic  matrix
components  aggrecan  and  type II collagen,  and  an  up-regulation  of catabolic  factors  such  as
matrix metalloproteinases  (MMPs) and  the ..  A disintegrin  and  metalloproteinases  with
thrombospondin  type 1 motif'  (ADAMTSs) 1.2.  In addition,  IL-l  activates  other  cytokines  such
as  IL-6 and  leukaemia  inducing  factor  (LIF) that induce  synergistic  effects  I.  While IL-l
certainly  causes  cartilage  degradation  and  the OA phenotype  in chondrocytes,  resent  studies  do
not indicate  a significant  up-regulation  ofIL-l  in naturally  occurring  OA2,4,s.
Matrix  metalloproteinase-13
Recent  studies  of catabolic  mediators  in naturally  occurring  OA suggest  that collagenase-
3 also  named  matrix metalloproteinase-13  (MMP-13), not IL-l,  is principally responsible  for
matrix degradation4, Many microarray  studies  involving nonnal and  OA human  articular
cartilage  and  primary chondrocytes  have  indicated  that MMP-13 genes  were  up-regulated  while
those  of IL-l  were  not. In addition,  immunohistochemistry  experiments  showed  that
chondrocytes in the superficial areas  of OA cartilage expressed  MMP-13  to a greater extent and
Also, the overexpression  ofMMP-13 alone  induces  OA in mites. more unifonnly  than 1r  14,
Thus,  utilizing exogenous  MMP-13 to produce  in vitro cartilage  degradation  may  be a valuable
tool in developing  therapeutics.
Metalloproteinases  (MMPs) constitute  a protein  superfamily  of endopeptidases  made  up
of closely  related  families  of collagenases,  gelatinases,  and  stromelysins  that contain  a zinc-
binding motif  in their catalytic sites and require calcium for ful1 activation 6.11.  Col1agenases,5
the  ability of cleaving  all three  a chains  of triple helical collagen  fibers. The preferred  substrate
ofMMP-13 is type n collagen.  which is cleaved  into characteristic  3/4 and 1/4  fragments7
MMP-13 is the most  potent  collagenase  against  type II collagen  and  it is also  observed  to cleave
type n collagen  faster  than any  other  member.  In addition  to directly degrading  the matrix. MMP-
13  ~  also  been  shown  to activate  signal  transduction  pathways  such  as  ERK Y2,  which causes
20. MMP-13  has a dedifferentiate  of chondrocytes  and  activates  pro-inflammatory  cytokines
restricted  distribution in the body relative  to other  MMPs J4and  is principally found  during
cartilage  development.  extracellular  matrix remodeling,  and  is highly expressed  in pathological
contexts including  OA 21
MMP-13 is synthes~  as  an inactive  pro-enzyme  that is activated  by cleavage  of a
peptide  at the  N-tenninus. MMP-13 can  be activated  by autoproteolytic  mechanisms,  several
other MMPs (including  MMP-2.  and MMP-3).  aminophenylmercuric acetate  (APMA).  and
trypsin 6. MMP-13 can  also  be  activated  with joint damage  and  the resulting  products  of
cartilage  degradation  such  as  collagen  fragments.  and  fibronectin  fragments  via MAP kinase
cascades  and  PKC  22, Once  activated,  MMP-13 can  be regulated  by tissue  inhibitors of
metalloproteinases  (nMPs)  2Oor  receptor-mediated endocytosis and degradation 13.20.  It has been
shown  that OA choodrocytes  have  a reduced  ability to bind and  degrade  MMP-13, further
contributing  to the overexpression  of  the protein  in the joint  20.
Despite  these  studies  that document  that MMP-13 plays  an integral  role in producing  the
OA phenotype,  most  studies  ofMMP-13 focus  on proteoglycan  cleavage  mechanisms  and  the
characteri7Btion  ofMMP-13 cell-surface  binding and  internalization2.3,7-9.  The  focus  of  this
honor's  thesis  was  to investigate  the potential  ofMMP-13 as  an acceptable,  and  potentially more
clinically relevant,  method  for in vitro studies  of cartilage  degradation.6
Rho GTPases
Rho GTPases  are  a subgroup  of the Ras  superfamily,  which in mammals  comprise  at
least  ten distinct proteins  23. Small  GTP-binding  proteins  cycle  between  a GTP bound  active
state,  and  a GDP bound  inactive  state. Activity of GTPases  is regulated  by the ratio of GTP
versus  GTD-bound  forms within the cell 23.  Hydrolysis  of GTP  to GDP is catalyzed  by GTPase
activating  factors  (GAPs)  while the exchange  of GDP for GTP is catalyzed  by guanine  nucleotide
exchange factors (GEFs) 23.24,
Three members of Rho GTPases  in particular, RhoA. Rac, and Cdc42, have been shown
to be important regulators of actin cytoskeleton 23-25.  Filamentous actin can be organized into
23. Rac has been observed to various discrete structures induced by different  Rho GTPases
activate the fomtation  of lame  IIi podia that appear as thin protrusive sheets  23,2S.  Cdc42 has been
shown  to induce  the fonnation  of filopodia. finger-like protrusions  containing  a tight bundle  of
long actin filaments 23.2S.  RhoA causes  the formation of actin stress  fibers, which are actin
bundles  that  transverse  the cell and  are  linked to the extracellular  matrix via focal adhesions  23,25.
IL-l  has  been  observed  to up-regulate  the activation  RhoA, resulting  in the increased
fonnation  of stress  fibers while down-regulating  the activation  ofRac and  Cdc42  in articular
chondrocytes16.  Since  IL-I  has  been  shown  to induce  an OA phenotype  in chondrocytes,  this
may  suggest  that in naturally  occurring  OA there  is an increase  in the formation  of actin stress
fibers. Morphology is tightly linked to phenotype  ofchondrocytes17,  thus it is of interest  how
MMP-13  affects the activation status of the Rho GTPases  and the organization of the
cytoskeleton  in articular  chondrocytes.
Objective
The objective  of this honor's  thesis  project  was  to investigate  the potential  ofMMP-13 as
an  acceptable  method  for in vitro studies  of cartilage  degradation.  The Fortier Lab has  shown
that human  recombinant  MMP-13 (hrMMP-13) induced  the OA phenotype  in chondrocytes  from7
equine  articular  cartilage4.  However,  hrMMP-13 was  synthesized  in an inactive  pro-enzyme  form
Trypsin cleaved  at nonspecific and trypsin was used to cleave the protein into its active form.
sites  and  created  a mixture  of inactive,  active,  and  degraded  MMP-13. In our study,  equine
MMP-13 was  cloned,  inserted  into a protein expression  vector  to express  the active  protein. It
was  the  broad  objective  of this honor's  thesis  to detennine  the effects  of eqrMMP-13  on matrix
molecule  expression  of chondrocytes,  and  on the activation  states  of the small G-proteins  of the
Rho family  (Cdc42, Rac, RhoA),  and to compare the results to those achieved after treatment
with IL-
The specific  aims  of this study  used  complimentary  approaches  to identify the level of
expression  of extracellular  matrix molecules  and  the activation  status  of Cdc42,  Rac,  and  RhoA in
equine  articular  chondrocytes  treated  with eqrMMP-13. To evaluate  the expression  of
extracellular  matrix molecules,  chondrocytes  were  plated  in monolayer  and  treated  with
eqrMMP-13,  and total RNA  was extracted and evaluated using quantitative RT  -PCR. The effect
ofMMP-13 on activation  status  of the small GTPases  was  evaluated  by treating  chondrocytes  in
monolayer,  retaining  active  GTP-bound  GTPases  from celllysates using  a GST fusion protein
containing  the binding domain  of a down-stream  target,  and  analyzing  the retained  proteins  by
polyacrylamide  gel electrophoresis  (PAGE) and  western  analysis. The  hypothesis  was  that
MMP-13  would produce similar effects as 11 1« on matrix  molecule expression and activity  of
small  GTPases,  and  thus  be an acceptable  model  to study  the molecular  mechanisms  involved
with OA and  better  mimic the native  articular  environment.
Methods
Cloning and expression  of eqrMMP-13 in Escherichia  coli
Equine  chondrocytes  were  treated  with hrIL-I  14Ing/J1L  hrIL-In  (R&D,8
was  isolated  using  a monophasic  solution  of phenol  and  guanidine  isothicyanate
according  to the manufacturer's  instructions  for RNA extraction  from cells in monolayer
(Invitrogen,  Carlsbad,  CA). cDNA of full length  MMP-13 was  constructed  using  gene
5' GOT TCC AGC CAC GCA TAG C 3'(Integrated  DNA Technologies,  INC.,
Coralville, IA), and  the Perkin  Elmer Gene  Amplification PCR  system  9600  set  at 55° for
30 minutes. cDNA of active  MMP-13 was  amplified  with PCR  by creating  a EcoRI site
immediately  upstream of the first codon after the propeptide  cleavage site with the
forward primer 5' GGA ATT CfA  CAA TOT nT  CCC  TCG AAC TCT CA 3' and
reverse  primer 5' rrc  AGA GAG  COG  COO  crr  CCT  CTG  AT 3'  (Integrated  DNA
Technologies,  INC.,), using  Platinwn Taq  (Invitrogen)  and  the Perkin  Elmer Gene
Amplification PCR  system  9600  set  at 95° for 2 minutes,  (95° 30 seconds,  55° 30
seconds,  72° 1 min)x 30 cycles. The  PCR  product  was  purified using  the QIAquik PCR
Purification  Kit (Qiagen,  Valencia,  CA). Then  the insert  was  ligated  into the TOPO  TA
vector  using  the TOPO  TA Cloning Kit (Invitrogen)  and  transformed  into TOP 10  cells
according  to manufactures  instructions. Next, the  TOPO  T  A plasmid  was  purified with
the Qiagen  miniprep  kit (Qiagen). Finally, the insert  was  restricted  digested  with EcoRl
and  Not 1 (Invitrogen)  and  ligated  into the  pGEX 4T  -1 plasmid  (Amersham  Biosciences,
Piscataway,  NJ) and  transfonned  into the JMl09 strain  of E. coli (Stl'atagene,  La Jolla
CA) with heat  shock  at 42° for 45 seconds.
E. coli pGEX plasmids  express  foreign DNA sequences  as  glutathione
S-transferase  (081)  fusion  proteins,  thus  08T:eqrMMP-13 was  expressed  and  purified
by batch  purification. The  protein  was  resolved  on a 12%  PAGE (180V, 9Ominutes),9
transferred  to polyvinylidene  difluoride membranes  (2~  60 minutes),  and  probed
using  rabbit anit-MMP-13 1° antibody  (Chemicon  International,  Temecula,  CA) and
donkey  anti-rabbit  2° antibody  (Amersham  Biosciences). The Fluorokine@  E Hwnan
Active MMP-13 Fluorescent  Assay  (R&D, Minneapolis,  MN) was  then  used  to test  the
activity of the purified protein  according  to manufacturer's  instructions.  except  samples
were  diluted by a factor of25 with the Caibmtor  Diluent RD5-25  (contained  in the
fluorescent  assay  kit)
Chondrocyte culture
Carillage  was  harvested  from 4 horses,  aged  6-1 months  euthanizoo  for reasons
unrelated  to this study.  Cbondrocytes  were isolated  by digestion  with collagenase
(Worthington  Biochemicals,  Lakewood,  NJ) as  described  21.  For the  extracellular  matrix
molecule  study,  cells  were  plated  on a 12  well plate  at 75% confluence,  in Ham's F-12
medium  containing  ]00/0  Fetal  Bovine Serum  (FBS), 3Omg/ml  L-glutamine,  3mg/ml
a-ketoglutaric  acid, 5mg/ml  ascorbic  acid,  and  0.025%  HEPES.  Thirty-si:x  and  84 homs
after  plating. samples  were  treated  in duplicate  with brIL-I a (I 0ng/mL),  eqrMMP-13
(5Ong/mL  or lOOng/mL)  in fresh  Ham's F-12 media  containing  2% FBS.  Chondrocytes
were  harvested  five days  after plating by rinsing with ImL  Ix PBS  and  lysed  with ImL
of a monophasic  solution  of phenol  and  guanidine  isothicyanate  (Invitrogen)  and  stored  at
-800c until utilized for RNA  isolation.
For the small  GTPase  activation  study,  cells were  plated  on lOOmrn  plates  at
95% contluencey  in Ham's F-12 medium  containing  100/0  FBS. Twenty-four  hours  after
plating the media  were  exchanged  for fresh  Ham's F-12  medium  containing  100/0  FBS10
Seventy-two  hours  after  plating the chondrocytes  were  treated  with GST:eqrMMP-13  (50
ng/mL) for 2 or 30 minutes.
RNA isolation and gene  expression  by relative quantification RT  -PCR
Total RNA was  isolated  using  a monophasic  solution  of phenol  and  guanidine
isothicyanate  according  to the manufacturer's  instructions  for RNA extraction  from cells
in monolayer  (Invitrogen)  according  to the manuf8l:;turer's  instructions  for RNA
extraction  from cells in monolayer. Total RNA of duplicate  samples  were  then  reversed
transcribed  and  amplified  using  a one-step  relative  quantification  RT  -PCR  technique  and
sequence  detection  system  (Applied Biosystems,  Foster  City, CA) with primers  and  dual-
labeled  fluorescent  probes  designed  using  designated  software  (Applied Biosystems)
from equine  specific  sequences  published  in Genbank  or sequenced  in the Fortier
laboratory. The RNA was  assessed  for expression  of aggrecan,  collagen  type fiB
(Col2Al),  MMP-3, MMP-13, and 18s. Values  for the threshold  cycle (CT)  for RT  -PCR
duplicates  were  averaged.  All samples  were  nonnalized  relative  to the 188  values  by
subtracting  188  CT  values  from sample  CT  values,  tissue  culture  duplicates  were  averaged,
and  evaluated  using  the 2-M  cr method  as described  29,
Rac and Cdc42 activation studies
Following treatment  and  lysis, whole  celllysates  were  centrifuged  at 16,100  x g,
4OC,  for minute.  Protein  concentration  in each  sample  were  quantified  using  a Bradford
assay.  1.0  mg (range .Omg-I.5mg) of each sample was loaded onto 40 J.Lg  of glutathione
S-transferase-  p21-activated  kinase  binding domain  (GST-PBD)  fusion proteins  andII
rocked  at 4°C  for 30 minutes. GST  -PRO  fusion  proteins  were  purified by standard
techniques  and  immobilized  on glutathione-agarose  beads.  The  glutathione  beads  were
rinsed with the pGEX lysis buffer fOUT  times and 20 J.LL  5X western blot loading dye was
added  to the  remaining  pellet. Retained  proteins  were  resolved  by a 15%  PAGE (180V,
9Ominutes)  and  transferred  to polyvinylidene  difluoride membranes  (200mA,  60
minutes). Nonspecific  binding was  blocked  with 5% milk in TBSrrween, and  the
membranes  were  probed  with 1  :500 dilution of mouse  anti-Cdc42  (BD Transduction
Labs,  San  Diego,  CA) in TBS/fween for a minimum of 15  hours. The  membranes  were
then  probed  with a 1:  1  000  dilution of sheep  anti-mouse  antibody  (Amersham
Biosciences)  with 1%  milk in TBS/fween for a minimwn of30 minutes  followed by 3
ten-minute  washes  with TBS/fween. Western  blots  resolved  with chemiluminescence
signals  were  assessed  using  a ChemiDoc  station  with QuantI Software  (BioRad,
Hercules,  CA). Finally, membranes  were  stripped  and  re-probed  with mouse  anti-Rac
antibody (BD Transduction Labs).
RhoA activation study
The  methods  used  to evaluate  the activation  of RhoA after treatment  with
GST:eqrMMP-13  were  similar to those  of the Rac  and  Cdc42  activation  studies.
Following treatment  and  lysis, the  whole celllysates  were  centrifuged  at 5000x  g, 4°C,
for 1 minute.  The  protein  concentration  in each  sample  was  quantified  using  a Bradford
assay.  3.5 mg of each  sample  was  loaded  onto 40 ~g of glutathione  S-transferase-
rhotecktin-binding-domain  (GST  -RBD) fusion  protein  and  rocked  at 4°C  for 30 minutes.
GST  -RBD fusion proteins  were  purified by standard  techniques  and  immobilized  on12
glutathione-agarose  beads.  The glutathione  beads  were  rinsed  with lysis buffer four
times.  Retained  proteins  were  analyzed  as  described  for Rac  and  Cdc42  studies  with
PAGE and  western  analysis  using  mouse  anti-RhoA  primary antibody  (Cytoskeleton  Inc.,
Denver,  CO).
Confocal microscopy
Chondrocytes were grown on coverslips in monolayer at 500/0  confluence, treated
with IL-la  (10 ng/ml) or OST:eqrMhlfP-13 (50 ng/ml) for 0 or 2 minutes, and fixed in
4% parafOmlaldehyde.  Chondrocytes were subsequently incubated with 0.1  % triton  and
then 70/0  BSA to block non-specific antibody binding. The actin cytoskeleton was stained
with Alexa Fluor 488 phalloidin (Invitrogen),  and the nucleus was identified with
To-PR0-3  nucleic acid stain (Invitrogen).  Coverslips were mounted with ProLong Gold
antifade reagent (Invitrogen), the cells were visualized using confocal microscopy.
Statistical analysis
Results from replicate samples  were averaged  and expressed  as a mean
plus/minus one standard  deviation of the four independent experiments that were
perfonned at separate  times using tissues from different animals.  Data from the
extracellular matrix molecule study were analyzed by a one-way analysis of variance
(ANOV A) to compare values between treatments (+/-IL-la  <X'  MMP-13),  all of which
were included in the model.  When an ANOV A bOO  a significant F-test, Tukey's post hoc
procedure was performed with p<O.O5  considered significant.  Data from the small13
GTPase  activation studies will  be evaluated after four independent experiments have
been  completed.
Results
GST:erqMMP-13
A 74 kD protein was purified from the E  coli transformed with the
pGEX-4T-l:erMMP-13  plasmid (Figure  1). This protein was bound by an anti-MMP-13
antibody and was the expected size of the active enzyme (47kD)7 plus the GST tag
(23kD).  In addition the Fluorokine@ E Human Active MMP-13  Fluorescent Assay
showed that the two batches  of purified  GST:erMMP-I3  used in these studies contained
334 and 400 ng/ml of active MMP-13  of the total 216 J1giml  prote~  respectively.
Extracellular matrix molecule  expression
As hypothesized, the effects of treatment with MMP-13  generally paralleled the
changes  in matrix molecule expression produced by IL-I  a (Figures  2-5).  Both the 50
and 100 ng/ml doses  ofMMP-13  significantly  increased  the mRNA  expression of the
catabolic mediator MMP-3  (Figure  2). Neither  10 ng/ml IL-la  Dor~ 50 Dg/ml MMP-13
changed  the level of endogenous  MMP-13  expression at a significance level of p<O.O5
(Figure 3).
The expression of the anabolic factor Co12AI was significantly  decreased  by
both ~ 50 ng/ml MMP-13  and 10 ng/ml IL-l  a (Figure  4). There was also no significant
difference  in aggrecan  expression  with treatment  of either  MMP-13 or IL-to. (Figure 5).14
GTPase  activity
MMP-13 (50 ng/ml) was  sufficient  to induce  significant  differences  in ma1rix
molecule  expression,  thus  this dose  was  chosen  for the GTPase  activity studies.
Preliminary  data  indicates  that MMP-13 reduces  the activity level of Rac  (Figures 6B).
The  ratio of GTP-bound  active  Rac,  to total Rac  in the culture  decreased  by an average  of
44% and  400/0  after  2 and  30 minutes  of treatment,  respectively  (n=2). The activity of
Cdc4  2 bas  been  observed  to be slightly increased  by treatment  with MMP  -13 at this stage
in the study (n=2) (Figure  6B). As expected, MMP-13  increased  the activity  of Rho  A
after 2 and 30 minutes of treatment (Figure  6A and B).
Confocal microscopy
Confocal microscopy images (Figure  7) show that treatment with both IL-la  (10
ng/ml) and MMP-13  (50 ng/ml) induce normal cultured chondrocytes to become
fibroblastic with increased  numbers of actin stress  fibers.  This increase  in stress  fiber
formation indicates an increase in the activation status  of RhoA.
Discussion
For the first time, active recombinant equine MMP-13  was cloned, inserted into a
vector, expressed  as a GST fusion protein. and confirmed to be active.  Thus, additional
factors used to cleave the proenzyme in past studies such as APMA  6 and trypsin 4 of
MMP-13,  were not needed  in these experiments.15
factors.
in MMP-3 expression  was  observed  between  chondrocytes  treated  with IL-la  and
27  and chondrocyte-
increase  MMP-3 expression  in equine  cultured  chondrocytes
synoviocyte  co-culture  systems  4.  The lack of such  observation  in this study  may  be due  to
the variation  of response  between  different animals.
treated  with either  IL-la  or exogenous  MMP-13. It was  unexpected  that IL-Ia  did not
increase  expression  ofMMP-13 as  such  phenomenon  has  been  well documented  studies
7.18.  The reason  this trend  wasn't proven of cultured  equine27  and  human  chondrocytes
endogenous  MMP-13 observed  between  animals.
It has  been  shown  that chondrocytes  react  differently to stimuli depending  on the
study  were  from horses  of similar ages,  animal  specific  differences  may  have  caused16
Treatment  with exogenous differences  in the physiological  state  of the chondrocytes.
MMP-13 also  did not produce  a significant  increase  in endogenous  MMP-13 expression,
which is consistent  with observations  in other  studies4. ThoughMMP-13 in
chondrocytes  is upregulated  in naturally  occurring  OA 7.18,  it was  expected  that treatment
with exogenous  MMP-13 would induce  an auto-inhibitory  affect.  The lack of this
observation  could  be the result  variability between  animals  and  the low levels  of
endogenous  MMP-13 present  in nonnal chondrocytes  18,
As expected  with the OA phenotype,  anabolic  matrix factors  were  decreased  or
unaffected  by IL-l  a and  MMP-13. Both IL-la  and  MMP-13 significantly decreased
expression  of Col2Al Our observed  decrease  in Col2Al expression  induced  by
MMP-13  is consistent with the standard cartilage degradation model IS.  27.
No significant  change  in the expression  of aggrecan,  the other  anabolic  matrix
component  observed  in this study,  was  observed  with either  IL-la  or MMP-13. A lack of
change  in aggrecan  expression  when  a decrease  in Col2Al  expression  was  observed
following treatment  with IL-l a has  also  been  observed  in other  studies  using  cultured
equine  chondrocytes  27.  Thus,  it is not surprising  that MMP-13 also  failed to induce  a
significant  change  in aggrecan  expression.  An absence  of an observed  change  in
aggrecan  expression  may also  be the result  of the temporal  effect and  differences  in
metabolism  between  cartilage  and  isolated  chondrocytes  as  discussed  with Col2Al
expression.  The data  presented  in the study  of extracellular  matrix molecule  expression
following treatment  with IL-la  and  MMP-13 was  based  only on mRNA expression.
While mRNA and  protein  levels  are  generally  well correlated,  one  must  not forget  that17
the proteins  the mRNA codes  for may be fW1her  regulated  at the translational  and
z posttranslationallevels  as  well as  other  protein  inhibitors
Preliminary  data  also  indicates  that MMP-13 produces  similar responses  to IL-la
in the activation  of small GTPases  as  indicated  by the  ratio of GTP/GDP-bound  forms.
Since  IL-Ia  is the  typical agent  used  to induce  the OA phenotype  in chondrocytes,  and
IL-l a has  been  shown  to decrease  the activation  of Rac  and  Cdc42  while increasing  the
activation  status  of Rho  A 16,  it was  expected  that MMP-13 would cause  similar changes
in the activation  of the Rho  GTPases.  Preliminary  results  show  a decrease  in Rac
activation,  parallel  to what was  observed  with treatment  ofIL-la  16 .  At the current  point
in the study,  a slight increase  in the activation  status  of Cdc42  has  been  observed  after
treatment  with MMP-13. This result  was  unexpected  and  additional  studies  are  needed  to
verify these  results. An increase  in RhoA activation  has  also  been  observed.  Confocal
microscopy  images  confinn an  increase  in the  activation  status  of RhoA and  show  a
definite increase  in actin stress  fiber fOmlation  following treatment  with MMP-13.
Therefore,  similar to IL-I  a, MMP-13 causes  a reorganization  of the actin cytoskeleton
and  stimulates  the fonnation  of stress  fibers.
In summary,  this study reports the successful  cloning and  expression  of active
equine  MMP-13. Treatment  with GST:eqrMMP-13  induced  the OA phenotype,  assessed
by altered  extracellular  matrix molecule  expression,  in chondrocytes  isolated  from
articular  cartilage. Further  experiments  are  cmrently  being  conducted  to determine  the
effect MMP-13 has  on the activation  of small GTPases  of the Rho subfamily  and  the
organization  of the actin cytoskeleton.  De-differentiation  of chondrocytes  and
destruction  of the surrounding  extracellular  matrix leads  to irreversible  cartilage18
damage20.  Thus  using  MMP-13 as  a model  to indoce  cartilage  degradation  will better
mimic the  native  articular  environment,  and  this then  may lead  to more  clinically
translatable  results  than  studies  using  IL-l  chondrocyte  cultures. Consequently,
understanding  how MMP-13 affects  the actin cytoskeleton  via the activation  status  of
the small GTPases  of the Rho subfamily  may lead  to novel OA therapeutics.
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Figure  legions
Figure 1: Western  blot analysis  of purified GST:eqrMMP-13  using  rabbit anti-MMP-13
1  ° antibody  and  donkey  anti-rabbit  2°antibody. WCL represents  the whole cell lysate.
The protein  bound  by the anti-MMP-13  antibody  is the expected  size  of active  MMP-13
(47kD) with the GST tag (23kD).
Figure  2: MMP-3  gene expression was significantly  increased  in cultures treated with
~ 50 ng/ml GST  :eqrMMP -13. IL-I  a treatment did not result in a significant difference
from cultures that were treated with MMP-13.  Bars represent  the mean ofn=4,  ~  S.D.
Letters indicate Tukey's post-hoc classification groups for those ANOV A's  with
significant  F -tests.
Figure 3: Endogenous  MMP-13 was  not significantly affected  by treatment  with either
IL-Ia  or exogenous  GST:eqrMMP-13.  Bars  represent  the mean  ofn=4,:t: S.D.  The
ANOV  A's lacked  significant  F-tests  at p<O.O5  between  all treatment  groups.
Figure 4: Collagen  type lIB (CQl2AI) gene  e~ion  was  significantly decreased  with
treatment  of both IL-Ia  and  ~ 50 ng/ml OST:eqrMMP-13.  Bars  represent  the  mean  of
n=4, :t:  S.D.  Letters  indicate  Tukey's jX)st-hoc  cl~ification  groups  for those  ANOV  A's
with significant  F-tests.
Figure  5: Aggrecan gene expression was not significantly  affected by treatment with
either IL-la  or GST:erMMP-13.  Bars represent  the mean ofn=4,  zS.D. The ANDV A '8
lacked significant F-tests at p<O.O5  between all treatment groups.
Figure  6: A. Western blot of active RhoA (RBD) and whole cell lysate (WCL)  after
treatment with  50 ng/ml GST:eqrMMP13  for 0, 2, and 30 minutes.  "c"  represents  the
positive control, which was derived from Cos7 cells transfected with constitutively  active
RhoA. "M"  = MagicMarkTM Western Staining (Invitrogen).  B. Graphic representation
of the ratio of active (GTP-bound) to total (GTP-bound and unbound) for Rac (n=2),
Cdc42 (n=2), and RhoA (n=l)  after treatment with GST:eqrMMP-13  for 0,2,  or 30
minutes.  Preliminary data suggest  that treatment with MMP-13  decreases  the activation
ofRac.  The activation status  ofCdc42  and RhoA after treatment with MMP-13  appears
to increase.
Figure  7: Confocal microscopy images of articular chondrocytes after treatment with
A. No treatment, B. IL-Ia  (lOng/ml),  C. GST:eqrMMP-13  (5Ong/ml). The nucleus was
stained with To-PR0-3  nocleic acid stain (red), while the actin cytoskeleton is identified
with Alexa Fluor 488 phalloidin (blue).  Normally,  cultured chondrocytes are polyhedral
with a few scattered  actin stress  fibers as observed in the no treatment control (A).
Treatment with either IL-Ia  or MMP-13  (8, C) results in more fibroblastic shaped  cells
and the fonnation of many cytoplasmic stress  fibers, which indicate an increase  in RhoA
activity.  Though no quantitative data were obtained, all images are representative  the
cells observed on their respective slides.24
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